<code id='E873CDE0E7'></code><style id='E873CDE0E7'></style>
    • <acronym id='E873CDE0E7'></acronym>
      <center id='E873CDE0E7'><center id='E873CDE0E7'><tfoot id='E873CDE0E7'></tfoot></center><abbr id='E873CDE0E7'><dir id='E873CDE0E7'><tfoot id='E873CDE0E7'></tfoot><noframes id='E873CDE0E7'>

    • <optgroup id='E873CDE0E7'><strike id='E873CDE0E7'><sup id='E873CDE0E7'></sup></strike><code id='E873CDE0E7'></code></optgroup>
        1. <b id='E873CDE0E7'><label id='E873CDE0E7'><select id='E873CDE0E7'><dt id='E873CDE0E7'><span id='E873CDE0E7'></span></dt></select></label></b><u id='E873CDE0E7'></u>
          <i id='E873CDE0E7'><strike id='E873CDE0E7'><tt id='E873CDE0E7'><pre id='E873CDE0E7'></pre></tt></strike></i>

          focus

          focus

          author:explore    Page View:6789

          On this week’s “Readout LOUD,” we’re live in San Francisco at STAT’s Breakthrough Summit West. AI is a big theme this year, everywhere, so on that note, we chat with our AI correspondent — and recent Pulitzer finalist — Casey Ross, who sat down on stage to discuss AI-centered drug discovery with both NVIDIA and Google-backed Isomorphic Labs.

          We also discuss this week’s biotech news, including yet more obesity drug data, this time from Roche, and the closing of Novartis’ acquisition of MorphoSys.

          advertisement

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          knowledge

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          UCB departs biotech trade group BIO
          UCB departs biotech trade group BIO

          AdobeWASHINGTON— UCBleftBIOattheendof2023,thesecondmajormembercompanytoexitafterPfizerpulledoutaswel

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Feng Zhang CRISPR delivery startup lays off quarter of staff

          AerawasformedtopursueananoparticledescribedbyFengZhangin2021.SusanWalsh/APAeraTherapeutics,astartupl